Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation
about
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainIdentification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein ReceptorPhysiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Identifying low density lipoprotein cholesterol associated variants in the Annexin A2 (ANXA2) gene.The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolismLiving the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)Decreased PCSK9 expression in human hepatocellular carcinoma.On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.Hepatic S1P deficiency lowers plasma cholesterol levels in apoB-containing lipoproteins when LDLR function is compromised.Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.An integrative computational analysis provides evidence for FBN1-associated network deregulation in trisomy 21β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cellsSerum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.PCSK9 targets important for lipid metabolismProprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblastsStairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population.Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.Expression and significance of annexin A2 in patients with gastric adenocarcinoma and the association with E-cadherin.Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradationThe PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells.An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.Annexins in Translational Research: Hidden Treasures to Be Found.Altered hepatic glucose homeostasis in AnxA6-KO mice fed a high-fat diet
P2860
02c824111d84b240c6f7c0a819ae5c3c8bab639c05065dc29a6bbae3326931f3c5c6d4f22472059e0dca102145adedee850868360056c6c64b6f15a71d22ac344ffa594c8931b36a955dd73c45c91b33336ca6ef7d5a04cdc375a63eeb74b269e10ab5973825bff817fd00ea92a86e2c95c5d0b444c4d22351b8d6c46569a37efa8d52fa933f7b5277d435c06f96c237f5713c9ffe199e3958570c1c662e0ce97ebe078f0bce458c8914d9df9be9d13dc34586fd9602dafa0e49001cd7e0b57f5a86d5c207210b8eb53b03e5f3add0cf4dce311ee37cfede679f08fabc07c440a7b7e7376ee0eeb62f9011c2d7da48d2c5e64404ec2546744508b8e63e1f9a72bb8ae6a2c6d69228722f00ae39e34e1909a23f41025f7d33c7c10a38d11822a2837f4e0a48c35aa1d463a7ff
P248
Q27339783-FD3AFB4F-824F-4F81-B58D-D492EF92986AQ27680601-5CB95C51-8C8F-45B0-9F5D-9C986264402FQ33599961-5A7808AF-53AD-483E-A06E-D4AA9108949DQ33732407-FBCEF08E-4B39-4D34-9A00-67568AE0C0B3Q33846421-1CCA55A5-BE17-484D-A06A-53DE6AE2B4E2Q34430377-77B8496B-A94C-4220-B297-A343B96D43F7Q34458693-5E08C324-288F-48E1-9AA2-5746D2D40398Q34723257-3A3792E9-B3E1-4FC8-962A-46AAD07F411BQ35870767-D8E2B87F-8A26-42A5-B4F1-3E532D0FCB57Q36035643-DBD5FB13-9BB6-4FB7-A66A-4C9AAC72ADAEQ36185317-63A5D1CC-ACD7-409D-8FDB-F2C0FE1EB51AQ36281706-D501C518-C686-4ABD-A768-3EDA598AFB76Q37096595-D63E1D9F-8DF6-4D37-BEE2-21120E83AEBAQ37225018-63954F14-F380-487E-A7DB-90723728CE64Q37250324-7E3E8DDF-9172-4A26-9499-4118E1500FBCQ37703261-C6D25D83-27BD-4715-94B2-3BF0D28D793AQ38109960-10BF6071-E3EE-4A54-9535-983C6B0AACA1Q38151675-D92384DF-388A-48D9-BD45-2732B1518D4AQ38846832-4AA83B05-171A-4680-9798-E2518ED1A7D8Q39051108-D34951B5-1E1A-4792-AC49-D4CB92643EF8Q40829286-B402C457-1044-4D24-9E21-6426AFC2A8F5Q41020560-5C9D02A1-D732-4760-94C2-36FF4DF54D4BQ42096061-0012BA41-99B9-439B-8AAB-15342DABCAEFQ42136107-5499C738-94A2-4DD3-A512-DCC0A9FE6A25Q42367561-8B82BAC0-9DE2-44B4-9BAD-37B73F950645Q42505455-669F2EB6-5FB9-4DE4-8679-8C4A120D8E7EQ45401315-BE9A3FE3-2043-4BB4-AF9A-69E6C14F6BC9Q53298782-530688EC-0D8A-44E1-8CCF-185D4486A714Q55714697-B99B43BA-75A7-49D5-8025-7BA8E3C4624FQ58778932-34A4C11A-D448-44D4-A5FB-21C26B915688
P2860
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@ast
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@en
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@en-gb
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@nl
type
label
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@ast
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@en
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@en-gb
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@nl
prefLabel
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@ast
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@en
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@en-gb
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@nl
P2093
P2860
P921
P3181
P1433
P1476
Annexin A2 is a natural extrah ...... duced LDL receptor degradation
@en
P2093
Bowman Miao
Claudio Mapelli
Gaétan Mayer
Hanny Wassef
Jean Davignon
Katherine A Hajjar
Maxime Denis
Rex Parker
Steve Poirier
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0041865
P407
P577
2012-01-01T00:00:00Z